Atle Fund Management AB
13F Reported Value
ⓘ$371.7M
Holdings
39
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Atle Fund Management AB disclosed 39 positions worth $371.7M in its Form 13F-HR for Q2 2026, led by $LLY (ELI LILLY & Co) at 9.6% of the equity portfolio, followed by $MRK and $JNJ. During the quarter the fund opened 3 new positions and exited 3 — including a new stake in $BIIB and a full exit from $AMGN. The portfolio is most concentrated in Healthcare (92.4% of disclosed assets). All figures are sourced directly from Atle Fund Management AB’s Form 13F-HR filing with the SEC under CIK 1381843.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 87.5#2
Quality
$35.8M29,821 sh - 59.9#898
Quality
$24.3M189,357 sh - 69.0#285
Quality
$21.7M85,425 sh - 72.6
Quality
$16.2M64,325 sh - 59.4
Quality
$15.1M146,102 sh - 65.1
Quality
$14.0M27,859 sh - —
Quality
$13.7M73,077 sh - 64.7
Quality
$13.6M62,781 sh - 76.5
Quality
$12.3M72,898 sh - 35.0
Quality
$11.8M100,807 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 ELI LILLY & Co$LLY | 87.5#2 | $35.8M | 29,821 |
 Merck & Co., Inc.$MRK | 59.9#898 | $24.3M | 189,357 |
 JOHNSON & JOHNSON$JNJ | 69.0#285 | $21.7M | 85,425 |
 AbbVie Inc.$ABBV | 72.6 | $16.2M | 64,325 |
 CVS HEALTH Corp$CVS | 59.4 | $15.1M | 146,102 |
 THERMO FISHER SCIENTIFIC INC.$TMO | 65.1 | $14.0M | 27,859 |
 Revolution Medicines, Inc.$RVMD | — | $13.7M | 73,077 |
 BIOGEN INC.$BIIB | 64.7 | $13.6M | 62,781 |
 NEUROCRINE BIOSCIENCES INC$NBIX | 76.5 | $12.3M | 72,898 |
 Mirum Pharmaceuticals, Inc.$MIRM | 35.0 | $11.8M | 100,807 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Atle Fund Management AB's 39 positions.
Showing top 10 of 39 holdings.
Sector Allocation
Healthcare
$343.3M
Consumer Staples
$14.4M
Technology
$14.0M
Full Holdings — Atle Fund Management AB (Q2 2026)
All 39 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $LLY | ELI LILLY & Co | $35.8M | 9.6% | -25% | 87.5 |
| 2 | $MRK | Merck & Co., Inc. | $24.3M | 6.5% | +459% | 59.9 |
| 3 | $JNJ | JOHNSON & JOHNSON | $21.7M | 5.8% | -8% | 69 |
| 4 | $ABBV | AbbVie Inc. | $16.2M | 4.3% | -41% | 72.6 |
| 5 | $CVS | CVS HEALTH Corp | $15.1M | 4.1% | +515% | 59.4 |
| 6 | $TMO | THERMO FISHER SCIENTIFIC INC. | $14.0M | 3.8% | +21% | 65.1 |
| 7 | $RVMD | Revolution Medicines, Inc. | $13.7M | 3.7% | -88% | — |
| 8 | $BIIB | BIOGEN INC. | $13.6M | 3.6% | NEW | 64.7 |
| 9 | $NBIX | NEUROCRINE BIOSCIENCES INC | $12.3M | 3.3% | -19% | 76.5 |
| 10 | $MIRM | Mirum Pharmaceuticals, Inc. | $11.8M | 3.2% | -49% | 35 |
| 11 |  $ALKS | Alkermes plc. | $11.2M | 3.0% | -12% | — |
| 12 |  $IONS | IONIS PHARMACEUTICALS INC | $10.9M | 2.9% | +392% | 23.4 |
| 13 |  $ONC | BeOne Medicines Ltd. | $10.0M | 2.7% | -16% | — |
| 14 |  $ISRG | INTUITIVE SURGICAL INC | $9.8M | 2.6% | -65% | 79.9 |
| 15 |  $SYK | STRYKER CORP | $9.5M | 2.6% | +13% | 72.1 |
| 16 |  $VRTX | VERTEX PHARMACEUTICALS INC / MA | $9.5M | 2.6% | -17% | 75.4 |
| 17 |  $EW | Edwards Lifesciences Corp | $9.3M | 2.5% | -3% | 69.4 |
| 18 |  $BBIO | BridgeBio Pharma, Inc. | $9.3M | 2.5% | +12% | 36.9 |
| 19 |  $KRYS | Krystal Biotech, Inc. | $8.9M | 2.4% | -36% | 79.2 |
| 20 |  $COR | Cencora, Inc. | $8.8M | 2.4% | +33% | 61.1 |
| 21 |  $NAMS | NewAmsterdam Pharma Co N.V. | $8.4M | 2.3% | +163% | — |
| 22 |  $ABVX | Abivax S.A. | $7.8M | 2.1% | +84% | — |
| 23 |  $INCY | INCYTE CORP | $6.5M | 1.7% | +12% | 77.4 |
| 24 |  $IRTC | iRhythm Holdings, Inc. | $6.4M | 1.7% | +142% | 54.8 |
| 25 |  $BSX | BOSTON SCIENTIFIC CORP | $6.2M | 1.7% | +262% | 77.5 |
| 26 |  $INSM | INSMED Inc | $6.2M | 1.7% | -40% | 39.4 |
| 27 |  $TNGX | Tango Therapeutics, Inc. | $6.2M | 1.7% | +564% | 17.6 |
| 28 |  $GILD | GILEAD SCIENCES, INC. | $5.8M | 1.6% | -4% | 57.4 |
| 29 |  $CAH | CARDINAL HEALTH INC | $5.6M | 1.5% | -78% | 62.4 |
| 30 |  $ORKA | Oruka Therapeutics, Inc. | $5.2M | 1.4% | NEW | — |
| 31 |  $SYRE | Spyre Therapeutics, Inc. | $5.1M | 1.4% | -9% | — |
| 32 |  $DXCM | DEXCOM INC | $4.8M | 1.3% | -88% | 76 |
| 33 |  $BCAX | Bicara Therapeutics Inc. | $4.3M | 1.2% | -88% | — |
| 34 |  $IDYA | IDEAYA Biosciences, Inc. | $3.5M | 0.9% | +203% | 36.1 |
| 35 |  $CELC | Celcuity Inc. | $3.5M | 0.9% | -76% | — |
| 36 |  $IRON | Disc Medicine, Inc. | $3.2M | 0.9% | -59% | — |
| 37 |  $PYXS | Pyxis Oncology, Inc. | $2.9M | 0.8% | +390% | 16 |
| 38 |  $CMPX | Compass Therapeutics, Inc. | $2.3M | 0.6% | +2407% | 28.1 |
| 39 |  $JBIO | Jade Biosciences, Inc. | $2.0M | 0.5% | NEW | — |
New Positions (3)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Atle Fund Management AB including:
Track Atle Fund Management AB's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Atle Fund Management AB and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Atle Fund Management AB
13F Pro is an AI hedge fund tracker and stock research platform. For Atle Fund Management AB (SEC CIK: 1381843), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Atle Fund Management AB's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.